Association of oral but not transdermal estrogen therapy with enhanced platelet reactivity in a subset of postmenopausal women

Menopause

Volumn 16, Issue 2, 2009, Pages 407-412

  Flaumenhaft, Robert ^a,d   Nachtigall, Margaret ^b   Lowenstein, Joanna ^b   Nachtigall, Lisa ^c   Nachtigall, Richard ^b   Nachtigall, Lila ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Estrogen therapy; Menopause; Platelet function; Transdermal estrogen

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HUMAN; HUMAN EXPERIMENT; POSTMENOPAUSE; PROTHROMBIN TIME; THROMBOCYTE FUNCTION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; BLOOD PLATELETS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 67649376670     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181833886     Document Type: Article

References (37)

1. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-980.
2. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-983.
3. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432.
4. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-3500.
5. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845.
6. Canonico M, Straczek C, Oger E, Plu-Bureau G, Scarabin PY. Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings. Maturitas 2006;54:372-379.
7. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
8. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
9. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712.
10. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365.
11. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602.
12. Khetawat G, Faraday N, Nealen ML, et al. Human megakaryocytes and platelets contain the estrogen receptor β and androgen receptor (AR): testosterone regulates AR expression. Blood 2000;95:2289-2296.
13. Jayachandran M, Miller VM. Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins. Platelets 2003;14:75-81.
14. Moro L, Reineri S, Piranda D, et al. Nongenomic effects of 17β-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor β and Src kinase. Blood 2005;105: 115-121.
15. Bar J, Lahav J, Hod M, Ben-Rafael Z, Weinberger I, Brosens J. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17β-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost 2000;84:695-700.
16. Yuan RY, Lee TK. Effect of estrogen on platelet aggregation in guinea pigs. Taiwan Yi Xue Hui Za Zhi 1989;88:978-981.
17. Elkeles RS, Hampton JR, Mitchell JR. Effect of oestrogens on human platelet behaviour. Lancet 1968;2:315-318.
18. Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont PJ. The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 2001;125:112-115.
19. A1/A1 individuals. Am Heart J 2006;152:136-139.
20. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996;84:289-297.
21. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet Function Analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319.
22. Kratzer MA. Is primary haemostasis controlled by a Fplatelet delay time-? Formulation of a new hypothesis. Platelets 2003;14:437-443.
23. Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia. 2001;7:170-179.
24. Franchini M. The platelet-function analyzer (PFA-100) for evaluating primary hemostasis. Hematology 2005;10:177-181.
25. Karger R, Donner-Banzhoff N, Muller HH, Kretschmer V, Hunink M. Diagnostic performance of the Platelet Function Analyzer (PFA-100) for the detection of disorders of primary haemostasis in patients with a bleeding history-a systematic review and meta-analysis. Platelets 2007; 18:249-260.
26. Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 2006;4:2043-2050.
27. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110:1392-1397.
28. Gianetti J, Parri MS, Sbrana S, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res 2006;118:487-493.
29. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4:2547-2552.
30. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the Platelet Function Analyzer PFA-100. Thromb Haemost 2000;83:316-321.
31. Sestito A, Sgueglia GA, Spinelli A, et al. Increased platelet reactivity in unstable angina patients is not related to C-reactive protein levels. Platelets 2006;17:336-339.
32. Thijs A, van Baal WM, van der Mooren MJ, et al. Effects of hormone replacement therapy on blood platelets. Eur J Clin Invest 2002;32: 613-618.
33. Williams MS, Vaidya D, Kickler T, Ouyang P. Long-term hormone replacement therapy does not cause increased platelet activation. Am Heart J 2005; 150:434-438.
34. Kaplan PB, Gucer F, Sayin NC, Yuce MA, Yardim T. Effects of oral continuous and transdermal cyclic 17-β estradiol and norethindrone acetate replacement therapy on platelet aggregation in postmenopausal women. J Reprod Med 2002;47:651-655.
35. Peverill RE, Smolich JJ, Malan E, Goldstat R, Davis SR. Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. Maturitas 2006;53:158-165.
36. Ohashi R, Sugimura M, Kanayama N. Estrogen administration enhances thrombin generation in rats. Thromb Res 2003;112:325-328.
37. Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception 2004; 70:97-106.